COVID-19 pandemic made biotech stocks very popular despite the serious economic downturn. Recent major positive 91.34% change of Navidea Biopharmaceuticals’ stock is another proof which could happen till second and third coronavirus waves. So, there is a huge space on this bandwagon for optimistic buyers who might enjoy even more dramatic changes.
Navidea Biopharmaceuticals’ internal funding does not happen since operating expenses usually exceed the gross profit by over $2 million. Only issuing shares and taking debts could help the biotech company to cover the operating costs. Soon, good news from new vaccine trials can make the total equity and stock price soar again.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life